Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient

Br J Haematol. 2020 Oct;191(2):e61-e64. doi: 10.1111/bjh.17000. Epub 2020 Jul 29.

Authors

Catherine K Gestrich¹, Navid Sadri¹, Mohamad G Sinno², Irina Pateva², Howard J Meyerson¹

Affiliations

¹ Department of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA.
² Department of Pediatrics, Division of Pediatric Hematology/Oncology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital/Case Western Reserve University, Cleveland, OH, USA.

PMID: 32729113
DOI: 10.1111/bjh.17000

No abstract available

Keywords: ATP5L-KMT2A; MLL*; acute lymphoblastic leukemia; reciprocal KMT2A fusion; t(11)(q23·3).

Publication types

Case Reports
Clinical Trial
Letter

MeSH terms

Allografts
Antibodies, Bispecific / administration & dosage*
Consolidation Chemotherapy
Cord Blood Stem Cell Transplantation*
Histone-Lysine N-Methyltransferase* / genetics
Histone-Lysine N-Methyltransferase* / metabolism
Humans
Infant
Male
Myeloid-Lymphoid Leukemia Protein* / genetics
Myeloid-Lymphoid Leukemia Protein* / metabolism
Oncogene Proteins, Fusion* / genetics
Oncogene Proteins, Fusion* / metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy

Substances

Antibodies, Bispecific
KMT2A protein, human
Oncogene Proteins, Fusion
Myeloid-Lymphoid Leukemia Protein
blinatumomab
Histone-Lysine N-Methyltransferase